Core Insights - Cingulate Inc. has appointed Bryan Downey as Chief Commercial Officer to advance the commercialization of CTx-1301, following FDA acceptance of its New Drug Application (NDA) with a target action date of May 31, 2026 [1][12] - The company has completed a $6 million financing transaction to strengthen its cash position and extend its cash runway into the second quarter of 2026, supporting its commercialization efforts pending FDA approval [2][8] Company Developments - Bryan Downey brings over 25 years of experience in commercial strategy and product launches, having held senior roles at Alfasigma USA, Jubilant Pharma, and Sanofi [3][4] - Cingulate's CTx-1301 is designed to provide rapid onset and all-day ADHD symptom control with a single daily dose, differentiating it from existing medications that often require multiple doses [5][12] - The company has partnered with Indegene to establish the commercial infrastructure and market access strategies necessary for the successful launch of CTx-1301 [5] Financial Overview - The $6 million financing was structured as a non-convertible, unsecured promissory note with a 9% annual interest rate, maturing in 18 months, allowing for monthly redemptions post-PDUFA date [8] - The proceeds from the financing will be utilized for working capital and general corporate purposes [8] Product Information - CTx-1301 utilizes Cingulate's proprietary Precision Timed Release™ (PTR™) platform, enabling three timed releases of medication from a single tablet to maintain focus throughout the day [5][12] - The global ADHD market is valued at over $23 billion annually, indicating significant market potential for Cingulate's innovative product [5]

Core Insights - Cingulate Inc. announced positive Phase 3 results for CTx-1301, a once-daily formulation of dexmethylphenidate for pediatric ADHD, achieving primary endpoints with significant symptom relief [1][3] - The ADHD market is valued at $23 billion, with CTx-1301 offering a potential advantage through its once-daily dosing, which may improve patient adherence [3] Group 1: Clinical Trial Results - CTx-1301 demonstrated dose-dependent improvements on ADHD ratings scale and Clinical Global Impression-Severity scales, providing symptom relief for up to 12 hours post-dose [1] - The randomized, double-blind, placebo-controlled study showed rapid onset of effect and sustained efficacy, with a safety profile consistent with other stimulant medications [2] Group 2: Product and Market Potential - The 37.5mg dose of CTx-1301 showed the largest effect size in symptom reduction, indicating substantial efficacy [3] - Cingulate's partnership with Indegene is structured to align commercial execution with growth milestones as the company approaches product launch [3] Group 3: Regulatory and Financial Aspects - The New Drug Application for CTx-1301 was accepted by the FDA, with a target PDUFA date of May 31, 2026, and a waiver of the standard PDUFA filing fee saving the company approximately $4.3 million [4] - Cingulate plans to share additional details from the Phase 3 study in future scientific publications and investor communications [6] Group 4: Company Overview - Cingulate Inc. utilizes its Precision Timed Release™ platform to develop next-generation pharmaceutical products aimed at improving patient outcomes in conditions requiring complex dosing [9] - CTx-1301 is in late-stage development for ADHD, with additional candidates targeting anxiety and other neuropsychiatric conditions [9]

Core Insights - Cingulate Inc. announced that data from its lead ADHD candidate CTx-1301 has been selected for podium presentation at the AACAP Annual Meeting, indicating significant scientific interest in the product [1][2][3] - CTx-1301 is designed as a once-daily, extended-release formulation aimed at improving treatment for ADHD by addressing limitations of current stimulant therapies [3][5] Company Overview - Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) platform [1][6] - The company is headquartered in Kansas City, Kansas, and is advancing a pipeline that includes candidates for ADHD and other neuropsychiatric conditions [6] Product Details - CTx-1301 (dexmethylphenidate HCl) utilizes the PTR™ platform to provide three precisely timed releases of medication throughout the day, aiming for rapid onset and full-day symptom control [5] - The product is currently being evaluated under the FDA's 505(b)(2) pathway for ADHD treatment [5] ADHD Context - ADHD affects an estimated 20 million individuals in the U.S., including around 8 million children and 12 million adults, characterized by inattention, hyperactivity, and impulsivity [4] - Current stimulant medications, while the gold standard, often require multiple daily doses and may not provide consistent coverage throughout the day [4]

Core Insights - Cingulate Inc. announced that data from its lead ADHD candidate CTx-1301 has been selected for podium presentation at the AACAP Annual Meeting, indicating growing scientific interest in the product [1][3] - CTx-1301 is a once-daily, extended-release formulation designed to simplify ADHD treatment for millions [1][4] Company Overview - Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) platform [1][6] - The company is headquartered in Kansas City, Kansas, and is advancing a pipeline that includes candidates for ADHD, anxiety, and other neuropsychiatric conditions [6] Product Details - CTx-1301 (dexmethylphenidate HCl) utilizes the PTR™ platform to deliver three precisely timed releases of medication throughout the day, aiming for rapid onset and full-day efficacy [5] - The product is currently being evaluated under the FDA's 505(b)(2) pathway for ADHD treatment [5] Clinical Presentation - The Phase 3 data for CTx-1301 will be presented by Dr. Ann Childress, a leading ADHD specialist, at the AACAP Annual Meeting [2][3] - The presentation will focus on the efficacy and safety of CTx-1301 in pediatric subjects with ADHD [2] ADHD Context - ADHD affects an estimated 20 million individuals in the U.S., including approximately 8 million children and 12 million adults, characterized by inattention, hyperactivity, and impulsivity [4] - Current stimulant medications often require multiple daily doses and may not provide consistent coverage throughout the day [4]

Core Insights - Cingulate Inc. announced that the FDA has accepted the New Drug Application (NDA) for CTx-1301, a treatment for ADHD, with a target action date of May 31, 2026 [1][3] - The NDA is being reviewed under the FDA's 505(b)(2) pathway, allowing Cingulate to leverage existing data on dexmethylphenidate while demonstrating novel clinical benefits [2][10] - CTx-1301 has shown significant improvements in ADHD symptoms during Phase 3 trials, indicating its potential to address gaps in current ADHD management [4][6] Regulatory Milestone - The acceptance of the NDA marks a significant regulatory milestone for Cingulate and the CTx-1301 program, validating the completeness of their submission [3][5] - The FDA's review will assess the efficacy, safety, and overall risk-benefit profile of CTx-1301 [7] Clinical Results - Phase 3 trials demonstrated that CTx-1301 provides rapid onset of effect and sustained efficacy throughout the day, addressing issues with current stimulant therapies [4][6] - No serious treatment-emergent adverse events were reported, indicating a favorable safety profile [6] Commercial Strategy - Cingulate is preparing for a timely launch of CTx-1301, having completed process transfer and scale-up production with its manufacturing partner [7] - The company is leveraging an AI-driven omnichannel platform to optimize prescriber reach and patient support, with early research indicating strong formulary receptivity for CTx-1301 [8] Market Context - ADHD affects approximately 20 million individuals in the U.S., with stimulant medications being the gold standard for treatment [9] - Current extended-release formulations often require multiple doses, highlighting the need for a once-daily solution like CTx-1301 [9][10]

Core Insights - Cingulate Inc. has entered into a strategic commercial supply agreement with Bend Bio Sciences for the manufacturing of its lead asset CTx-1301, pending FDA approval [1][3] - CTx-1301 is a novel, extended-release formulation of dexmethylphenidate aimed at addressing limitations of current ADHD therapies, with an NDA submitted to the FDA on July 31, 2025 [2][3] - The agreement ensures Bend Bio Sciences will be the exclusive manufacturer of CTx-1301 in the U.S. through 2028, contingent on FDA approval, providing manufacturing security and operational efficiency for Cingulate [3][4] Company Overview - Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) drug delivery platform [1][9] - The company aims to improve treatment outcomes for patients with conditions requiring complex dosing regimens, starting with ADHD and potentially expanding to anxiety disorders [9] Product Details - CTx-1301 utilizes Cingulate's PTR technology to deliver dexmethylphenidate in a multi-core formulation designed for precise release at defined intervals, addressing the challenge of providing an entire active-day duration of action [6][7] - The formulation is designed to enhance patient care by delivering medication in a single tablet, improving adherence and treatment efficacy [6][8] Market Context - ADHD affects over 20 million patients in the U.S., with a significant portion being adults; current treatment options are often inadequate, highlighting the need for innovative therapies like CTx-1301 [5][6] - The prevalence of adult ADHD is growing faster than that of children and adolescents, indicating a substantial market opportunity for effective treatment solutions [5]

Core Insights - Cingulate Inc. is making significant progress towards the commercial launch of its lead ADHD asset, CTx-1301, with a focus on its Precision Timed Release (PTR) platform designed for once-daily dosing [1][5]. Financial Performance - Cingulate reported $8.9 million in cash and $3.5 million in working capital at the end of 2Q25, which is expected to fund operations into late 2025 [5]. Product Development - The company submitted its New Drug Application (NDA) for CTx-1301 on July 31, 2025, with FDA acceptance anticipated in 4Q25 and a potential PDUFA date in mid-2026 [5]. - Positive results from the Phase 3 pediatric trial and fed/fast study have reinforced CTx-1301's efficacy and flexible dosing capabilities [5]. Commercialization Strategy - Cingulate is actively planning for commercialization in collaboration with Indegene, aiming for a product launch in mid-2026 [5]. - The company is also exploring strategic partnerships to expand its global presence [1].

[PART I - FINANCIAL INFORMATION](index=5&type=section&id=PART%20I) [Item 1. Financial Statements](index=5&type=section&id=Item%201%20Financial%20Statements) The unaudited consolidated financial statements show a net loss of $8.6 million for the six months ended June 30, 2025, highlighting the company's pre-revenue status and going concern uncertainty Consolidated Balance Sheet Highlights (unaudited) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $8,900,183 | $12,211,321 | | Total assets | $13,468,208 | $14,864,489 | | Total liabilities | $7,956,334 | $7,408,984 | | Total stockholders' equity | $5,511,874 | $7,455,505 | Consolidated Statements of Operations Highlights (unaudited) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $2,700,939 | $1,881,093 | $4,923,565 | $3,688,078 | | General and administrative | $1,949,035 | $1,325,087 | $3,432,444 | $2,466,319 | | Operating loss | $(4,649,974) | $(3,206,180) | $(8,356,009) | $(6,154,397) | | Net loss | $(4,788,735) | $(3,209,677) | $(8,591,426) | $(6,182,154) | | Net loss per share | $(1.09) | $(5.47) | $(2.14) | $(12.28) | Consolidated Statements of Cash Flows Highlights (unaudited) | Cash Flow Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(9,403,539) | $(10,488,400) | | Net cash used in investing activities | $(5,925) | $(154,133) | | Net cash provided by financing activities | $6,098,326 | $10,971,045 | | Net (decrease) increase in cash | $(3,311,138) | $328,512 | [Notes to Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) - The company is a pre-revenue biopharmaceutical firm that has incurred losses since inception, and its **ability to continue as a going concern is in substantial doubt**[23](index=23&type=chunk)[25](index=25&type=chunk) - On December 20, 2024, the company issued an **unsecured promissory note for $5,480,000** to Streeterville Capital, LLC, with an outstanding balance of $5,747,984 as of June 30, 2025[40](index=40&type=chunk)[44](index=44&type=chunk) - The company **submitted the New Drug Application (NDA) for its lead candidate, CTx-1301**, to the FDA on July 31, 2025[71](index=71&type=chunk) - Subsequent to the quarter end, **significant management changes occurred**, including placing the CEO on administrative leave and terminating the COO's employment[71](index=71&type=chunk)[72](index=72&type=chunk) - After the quarter, the company entered a new purchase agreement with Lincoln Park for up to **$25.0 million of common stock** and exchanged $1,225,000 of its promissory note for shares[69](index=69&type=chunk)[70](index=70&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=21&type=section&id=Item%202%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the NDA submission for CTx-1301, a Q2 2025 net loss of $4.8 million, and the substantial doubt about its going concern status due to limited cash reserves - The company is a biopharmaceutical firm using its Precision Timed Release (PTR) drug delivery platform, with an initial focus on ADHD and anxiety treatments[76](index=76&type=chunk) - The **New Drug Application (NDA) for the lead product candidate, CTx-1301, was submitted** to the FDA on July 31, 2025[86](index=86&type=chunk) - **Significant management changes occurred in August 2025**, including placing CEO Shane Schaffer on administrative leave and appointing CFO Jennifer Callahan as interim CEO[81](index=81&type=chunk)[82](index=82&type=chunk) - The company believes its current cash will fund operations into late 2025 and will need to raise an **additional $1.5 million** to advance commercialization efforts into early 2026[79](index=79&type=chunk)[122](index=122&type=chunk) [Results of Operations](index=26&type=section&id=Results%20of%20Operations) The net loss increased to $4.8 million for the quarter and $8.6 million for the six-month period, driven by higher R&D and G&A expenses related to the CTx-1301 NDA submission Comparison of Operating Results (Three Months Ended June 30) | (in thousands) | 2025 | 2024 | Increase | % Increase | | :--- | :--- | :--- | :--- | :--- | | Research and development | $2,701 | $1,881 | $820 | 43.6% | | General and administrative | $1,949 | $1,325 | $624 | 47.1% | | Net Loss | $(4,789) | $(3,209) | $1,580 | 49.2% | Comparison of Operating Results (Six Months Ended June 30) | (in thousands) | 2025 | 2024 | Increase | % Increase | | :--- | :--- | :--- | :--- | :--- | | Research and development | $4,924 | $3,688 | $1,236 | 33.5% | | General and administrative | $3,432 | $2,466 | $966 | 39.2% | | Net Loss | $(8,592) | $(6,182) | $2,410 | 39.0% | [Liquidity and Capital Resources](index=30&type=section&id=Liquidity%20and%20Capital%20Resources) The company holds $8.9 million in cash, sufficient until late 2025, but requires an additional $1.5 million to advance commercialization, raising substantial doubt about its going concern status - The company had **cash and cash equivalents of $8.9 million** as of June 30, 2025[122](index=122&type=chunk) - Capital is being raised through an At-the-Market (ATM) agreement and a Lincoln Park Capital purchase agreement, which **raised net proceeds of $4.2 million in Q2 2025**[120](index=120&type=chunk)[121](index=121&type=chunk) - The company's history of losses and need for additional capital raise **substantial doubt about its ability to continue as a going concern**[133](index=133&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=33&type=section&id=Item%203%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company indicates it has no significant market risk exposure requiring quantitative and qualitative disclosure - The company has determined that quantitative and qualitative disclosures about market risk are **not applicable**[136](index=136&type=chunk) [Item 4. Controls and Procedures](index=33&type=section&id=Item%204%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal controls during the quarter - Management concluded that the company's **disclosure controls and procedures were effective** as of June 30, 2025[137](index=137&type=chunk) - **No changes in internal control over financial reporting** occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[138](index=138&type=chunk) [PART II - OTHER INFORMATION](index=35&type=section&id=PART%20II) [Item 1. Legal Proceedings](index=35&type=section&id=Item%201%20Legal%20Proceedings) The company recorded no loss contingencies for legal proceedings but disclosed a reasonably possible contingent bonus plan of $722,824 - The company had **no accrued loss contingencies** for legal proceedings as of June 30, 2025[38](index=38&type=chunk)[139](index=139&type=chunk) - A **contingent bonus plan estimated at $722,824** exists to repay employees for previous salary reductions, but it has not been accrued as payment was not deemed probable[39](index=39&type=chunk) [Item 1A. Risk Factors](index=35&type=section&id=Item%201A%20Risk%20Factors) The company highlights an expanded risk related to retaining key management following recent executive changes, with no other material changes to previously disclosed risks - The company highlights the **risk of failing to attract and retain key management personnel**, citing recent executive changes in August 2025[142](index=142&type=chunk) - Except for the expanded risk factor on key personnel, there were **no other material changes** to the risk factors previously disclosed in the Form 10-K[141](index=141&type=chunk) [Item 5. Other Information](index=36&type=section&id=Item%205%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the second quarter of 2025 - **No director or officer adopted or terminated a Rule 10b5-1 trading arrangement** during the second quarter of 2025[147](index=147&type=chunk) [Item 6. Exhibits](index=36&type=section&id=Item%206%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including governance documents, material agreements, and required certifications - The report lists exhibits filed, including corporate bylaws, material agreements, and required officer certifications[148](index=148&type=chunk)

[Overview and Recent Highlights](index=1&type=section&id=Overview%20and%20Recent%20Highlights) [Key Developments](index=1&type=section&id=Key%20Developments) Cingulate submitted an NDA for CTx-1301, anticipating Q4 2025 FDA acceptance and mid-2026 approval, supported by $25 million equity financing - Submitted a New Drug Application (NDA) to the FDA for its lead asset CTx-1301 for ADHD on **July 31, 2025**[1](index=1&type=chunk)[2](index=2&type=chunk) - Anticipates an FDA decision on NDA acceptance in **Q4 2025**, with a potential Prescription Drug User Fee Act (PDUFA) date in **mid-2026**[1](index=1&type=chunk) - Entered into a 36-month purchase agreement with Lincoln Park Capital for up to **$25.0 million** of common stock, providing opportunistic access to capital[2](index=2&type=chunk)[3](index=3&type=chunk) [Clinical Trial Updates](index=1&type=section&id=Clinical%20Trial%20Updates) Positive Q2 CTx-1301 clinical results from fed/fast and Phase 3 pediatric studies supported the NDA submission - Announced positive top-line results from a **high-dose (50mg) fed/fast study**, demonstrating that CTx-1301 can be administered with or without food[4](index=4&type=chunk) - Results from the **Phase 3 pediatric study** showed a marked improvement of ADHD symptoms at **week five**, highlighting the product's potential benefits[4](index=4&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Performance) [Second Quarter 2025 Financial Results](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results) Cingulate's Q2 2025 net loss increased to $4.8 million due to higher NDA-related expenses, with $8.9 million cash covering operations into late 2025 - Cash and cash equivalents stood at **$8.9 million** as of **June 30, 2025**. The company projects this will satisfy capital needs into **late 2025** and will need to raise an additional **$1.5 million** to advance commercialization efforts into **early 2026**[5](index=5&type=chunk) Quarterly Expense Analysis | Expense Category | Q2 2025 (USD) | Q2 2024 (USD) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | R&D Expenses | $2.7 million | $1.9 million | +43.6% | Increased clinical and regulatory costs for NDA submission | | G&A Expenses | $1.9 million | $1.3 million | +47.1% | Increase in legal and financial advisory fees | | **Net Loss** | **$4.8 million** | **$3.2 million** | **+50.0%** | Primarily due to increased R&D costs | [Consolidated Financial Statements](index=2&type=section&id=Consolidated%20Financial%20Statements) Consolidated financials show declining position and worsening operating results, with Q2 2025 operating loss increasing to $4.6 million due to higher expenses [Consolidated Balance Sheet](index=2&type=section&id=Consolidated%20Balance%20Sheet) Consolidated Balance Sheet Data | Account | June 30, 2025 (USD) | December 31, 2024 (USD) | | :--- | :--- | :--- | | Cash and cash equivalents | $8,900,183 | $12,211,321 | | Total assets | $13,468,208 | $14,864,489 | | Total liabilities | $7,956,334 | $7,408,984 | | Working Capital | $3,489,921 | $7,688,698 | | Total stockholders' equity | $5,511,874 | $7,455,505 | [Consolidated Statements of Operations](index=3&type=section&id=Consolidated%20Statements%20of%20Operations) Consolidated Statements of Operations Data | Account | Three Months Ended June 30, 2025 (USD) | Three Months Ended June 30, 2024 (USD) | | :--- | :--- | :--- | | Research and development | $2,700,939 | $1,881,093 | | General and administrative | $1,949,035 | $1,325,087 | | **Operating loss** | **($4,649,974)** | **($3,206,180)** | | **Net loss** | **($4,788,735)** | **($3,209,677)** | [Corporate and Product Information](index=3&type=section&id=Corporate%20and%20Product%20Information) [About CTx-1301 and PTR™ Platform](index=3&type=section&id=About%20CTx-1301%20and%20PTR%E2%84%A2%20Platform) CTx-1301, an ADHD drug on Cingulate's PTR™ platform, provides once-daily dosing with three timed releases for full-day efficacy - CTx-1301 is a multi-core formulation of dexmethylphenidate designed to deliver **three releases of medication** at predefined times to provide rapid onset and entire active-day efficacy from a single tablet[13](index=13&type=chunk) - The PTR™ drug delivery platform uses a proprietary **Erosion Barrier Layer (EBL)** to control drug release at precise, pre-defined intervals[14](index=14&type=chunk) [About ADHD Market](index=3&type=section&id=About%20ADHD%20Market) The ADHD market offers significant opportunity with over 20 million U.S. patients, led by the larger, faster-growing adult segment - ADHD affects over **20 million diagnosed patients** in the U.S., with **12 million adults** and over **8 million under the age of 17**[12](index=12&type=chunk) - Market trends show the **adult ADHD segment is larger and growing faster** than the child and adolescent segments combined[12](index=12&type=chunk) [Company Overview](index=4&type=section&id=Company%20Overview) Cingulate Inc. is a biopharmaceutical company leveraging its PTR™ platform to develop next-gen products, initially focusing on ADHD with plans for anxiety disorders - Cingulate is a biopharmaceutical company using its proprietary **PTR™ platform** to develop products designed to improve the lives of patients with conditions requiring complex daily dosing[15](index=15&type=chunk) - The company's initial focus is on **ADHD**, with plans to evaluate additional therapeutic areas like **anxiety disorders** for future product candidates[15](index=15&type=chunk)

Core Viewpoint - Cingulate Inc. has submitted a New Drug Application (NDA) to the FDA for its lead asset CTx-1301, an innovative ADHD treatment, with an anticipated FDA decision in Q4 2025 and a potential PDUFA date in mid-2026 [1][2][4]. Recent Highlights - The NDA submission for CTx-1301, a novel extended-release tablet formulation of dexmethylphenidate, aims to address limitations of current ADHD therapies by providing fast onset and entire active-day efficacy [2][4]. - Cingulate entered into a purchase agreement with Lincoln Park Capital to purchase up to $25 million of common stock over a 36-month term, allowing the company to manage its capital needs effectively [3][4]. Financial Results - As of June 30, 2025, Cingulate reported approximately $8.9 million in cash and cash equivalents, a decrease of $3.3 million from December 31, 2024, and expects to need an additional $1.5 million to support commercialization efforts for CTx-1301 [5]. - Research and development expenses increased by 43.6% to $2.7 million for the three months ended June 30, 2025, primarily due to costs associated with the NDA submission [6]. - General and administrative expenses rose by 47.1% to $1.9 million for the same period, mainly due to higher legal and financial advisory fees [7]. - The net loss for the three months ended June 30, 2025, was $4.8 million, compared to $3.2 million for the same period in 2024, reflecting increased R&D costs [7]. Product and Technology Overview - CTx-1301 utilizes Cingulate's proprietary Precision Timed Release™ (PTR™) platform, designed to deliver dexmethylphenidate in a way that optimizes patient care with a single tablet providing multiple releases throughout the day [15][17]. - The PTR technology incorporates an Erosion Barrier Layer (EBL) that controls drug release at precise times, aiming to improve treatment outcomes for ADHD and potentially other therapeutic areas [17][18]. Market Context - ADHD affects millions, with over 20 million diagnosed in the U.S., including 12 million adults and over 8 million children under 17, indicating a significant market opportunity for effective treatments [14].